A lot has changed in the biotech industry over the last thirty or forty years. Those who can look back on a long career in the field, such as Diane Fabel, note that there are also some things that have remained the same, including “the passion of the faculty and the entrepreneurs to get that technology to market, even though it’s become very clear how daunting the task is and how many hundreds of millions of dollars it takes and 95% failure rates.”